<DOC>
	<DOCNO>NCT00545389</DOCNO>
	<brief_summary>Evaluate percentage subject remission end 8-week treatment period three dose group ( SPD476 1.2 g/day , 2.4 g/day 4.8 g/day , administer daily ) .</brief_summary>
	<brief_title>Phase II Dose-Ranging Study Subjects With Mild Moderate Ulcerative Colitis Treated With SPD476</brief_title>
	<detailed_description />
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis , Ulcerative</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<mesh_term>Mesalamine</mesh_term>
	<criteria>male &amp; female subject great equal 18 year age newly diagnose relapse mild moderate ulcerative colitis general medical assessment satisfactory clinically significant relevant abnormality severe ulcerative colitis subject relapse &gt; 6 week use systemic rectal steroid within last 4 week prior baseline subject proctitis , previous colonic surgery , Crohn 's disease , bleed disorder , active ulcer disease subject hypersensitive salicylates/aspirin subject moderate severe renal impairment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2007</verification_date>
</DOC>